Pharma Journalist -

Avidity Biosciences, Inc. announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation (ODD) to delpacibart etedesiran (del-desiran) for…
Read More...

Engine Biosciences (Engine), a Singapore- and Silicon Valley-based biotechnology company pioneering precision medicine for cancer, announced a new partnership with the Experimental Drug…
Read More...

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic…
Read More...

ABL Bio Inc., a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement…
Read More...

CAS, a division of the American Chemical Society specializing in scientific content and knowledge management, and Cleveland Clinic, an academic health system with a global footprint,…
Read More...

Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world’s largest contract development and manufacturing…
Read More...

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD).…
Read More...

Sangamo Therapeutics, Inc. announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”), allowing Lilly to leverage Sangamo’s novel proprietary neurotropic…
Read More...

NBE Therapeutics (NBE) a wholly owned subsidiary of  Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel. This milestone reinforces its commitment to…
Read More...

Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, announced the successful…
Read More...